Large-scale randomised controlled trials such as the STEP programme (semaglutide) and SCALE trials (liraglutide) reported pancreatitis as an uncommon adverse event (occurring in 0.1-1% of patients), with no clear signal for increased risk compared to placebo
If you stack GHRP-6 with a GHRH analog in separate vials, double the syringe and vial planning for the second compound
Healthcare professionals and patients are encouraged to report suspected adverse reactions via the Yellow Card Scheme (yellowcard.mhra.gov.uk), and the overall benefit-risk profile remains favourable for appropriate patients
Other studies, none of which were RCTs, reported variable results
For litigation and regulatory analysis, that distinction matters significantly
Instead of expertise, influencers tend to rely solely on personal narrative